Successful response to pegylated interferon alpha in a patient with recurrent paraganglioma
- 1 February 2017
- journal article
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 24 (2) , L7-L11
Abstract
Introduction: Early and accurate identification of recurrences in patients with aggressive paraganglioma (PGL) poses significant challenges. Moreover, the most appropriate therapeutic strategy for recurrent PGL remains to be established. Results: We report the case of 52-year-old man with a history of recurrent, sporadic, left retroperitoneal PGL that relapsed twice (at eight and nine years after the first surgical intervention). At the time of the second recurrence, 2-deoxy-2-[fluorine-18]fluoro-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT) demonstrated a pathologically increased tracer uptake in multiple nodular lesions (10−15 mm in size) located close to the remnant of the left renal pedicle and in the left lombar paravertebral region. Moreover, PET/CT showed a hypermetabolic left supraclavicular lymph node (suggestive of a metastatic disease). Owing to the high surgical risk inherent in a third surgical intervention, the French network for adrenal cancers (COMETE-Cancer) board proposed medical treatment with pegylated interferon alpha (Pegasys; 180 µg per week). After one year of treatment, a 30% decrease in urinary normetanephrine levels was observed. In addition, a marked morpho-metabolic regression of nearly all of the retroperitoneal lesions as well as of the left supraclavicular lymph node was evident. Unfortunately, the patient developed significant signs of drug intolerance, leading to dose tapering and treatment discontinuation. Conclusion: This is the first case of recurrent PGL that showed significant biological and imaging responses to medical treatment with pegylated interferon alpha. Further research on the potential usefulness of this therapeutic approach in patients with relapsing PGL or pheochromocytoma is warranted.Keywords
This publication has 10 references indexed in Scilit:
- Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and ParagangliomaClinical Cancer Research, 2015
- SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T)Laboratory Investigation, 2015
- THERAPY OF ENDOCRINE DISEASE: Treatment of malignant pheochromocytoma and paragangliomaEuropean Journal of Endocrinology, 2014
- Interferon alpha and rapamycin inhibit the growth of pheochromocytoma PC12 line in vitroEndokrynologia Polska, 2013
- Updated and New Perspectives on Diagnosis, Prognosis, and Therapy of Malignant Pheochromocytoma/ParagangliomaJournal of Oncology, 2012
- SDHA Immunohistochemistry Detects Germline SDHA Gene Mutations in Apparently Sporadic Paragangliomas and PheochromocytomasThe Journal of Clinical Endocrinology & Metabolism, 2011
- SDHA is a tumor suppressor gene causing paragangliomaHuman Molecular Genetics, 2010
- VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumorsSurgery, 2002
- Potential of Interferon-?? in Solid TumoursBioDrugs, 2002
- Potential of Interferon-?? in Solid TumoursBioDrugs, 2002